Refine your search
Collections
Co-Authors
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Rajput, Neetu
- P53 and It’s Applications in Cancer Therapy
Abstract Views :412 |
PDF Views:0
Authors
Affiliations
1 Department of Pharmacology and Toxicology, College of Veterinary Science and Animal Husbandry, Rasalpura - 453446, Mhow, Madhya Pradesh, IN
2 Department of Pharmacology and Toxicology, GADVASU, Ludhiana - 141012, Punjab, IN
1 Department of Pharmacology and Toxicology, College of Veterinary Science and Animal Husbandry, Rasalpura - 453446, Mhow, Madhya Pradesh, IN
2 Department of Pharmacology and Toxicology, GADVASU, Ludhiana - 141012, Punjab, IN
Source
Toxicology International (Formerly Indian Journal of Toxicology), Vol 22, No 2 (2015), Pagination: 9-18Abstract
P53 is a tumour suppressor protein encoded by the TP53 gene, which is one of the most commonly mutated gene in human and animal cancers. Missense Mutation of the p53 gene is the most prevalent genetic abnormalities which gives rise to full length p53 containing single amino acid substitution within the sequence-specific DNA binding domain (|Greenblatt et al., 1994)14. p53 plays anti-cancer role, through several mechanisms namely by activating DNA repair, initiating apoptosis and inducing growth arrest. By managing the DNA damage, p53 gene plays an important role in maintaining integrity and stability of the genome and therefore, it has been described as "the guardian of the genome". Restoring p53 function is a major step in the treatment of many cancers by following different strategies like, gene replacement therapy using wild-type p53, reactivation of p53 function, inhibition of p53-Mdm2 interaction etc. Advexin is an Adeno-p53 vector, recognized as an orphan drug by USA, Food and Drug administration in 2003, provides delivery of wild-type p53 to cancer cells and demonstrates anticancer activity following adequate expression of p53 (Nemunaitis and Nemunaitis, 2008)27. Similarly, MI-319 restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals (Mohammad et al., 2009)25. These strategies of p53-based cancer therapy differ greatly between themselves both in the mode of action and the degree of success seen in experimental models. Cancer therapy based around p53 proves to be more efficacious, especially in terms of specificity. But the innovation of successful p53-based cancer therapies is only limited by our understanding of p53 biology and the creative use of such knowledge. In future, p53-based cancer therapy can be a valuable option for the treatment of a variety of tumours in human as well as animals.Keywords
P53/Cancer Therapy.
References
- Amaral. The role of p53 in apoptosis. Discovery Med. 2010; 9(45):145–52.
- Bennett M, Macdonald K, Chan SW, Luzio JP, Simari R, Weissberg P. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science. 1998; 282:290–3.
- Bertholet S, Iggo R, Corradin G. Cytotoxic T lymphocyte responces to wild-type and mutant mouse p53 peptides. Eur J Immunol. 1997; 27:798–801.
- Bottger A, Bottger V, Sparks A. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr Biol. 1997; 7:860–9.
- Bunz F. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 1998; 282:1497–501.
- Bykov VJ, Selivanova G, Wiman KG. Small molecules that reactivate mutant p53. Eur J Cancer. 2003; 39:1828–34.
- Cai DW, Mukhopadhyay T, Liu YJ. Stable expression of the wild-type p53 gene in human lung-cancer cells after retrovirus mediated gene-transfer. Human Gene Ther. 1993; 4:617–24.
- Chen J, Wu X, Lin J, Levine AJ. Mdm2 inhibits the G1 arrest and apoptosis functions of the p53 tumour suppressor protein. Mol Cell Biol. 1996; 16:2445–52.
- Ciernik IF, Berzofsky J, Carbone DP. Mutant oncopeptide immunization induces CTL specifically lysing tumour-cells endogenously expressing the corresponding intact mutant p53. Hybridoma. 1995; 14:139–42.
- Conseiller E, Debussche L, Landais D. CTS-1: A p53-derived chimeric tumour suppressor gene with enhanced in vitro apoptotic properties. J Clin Invest. 1998; 101:120–7.
- Cui R, Widlund HR, Feige E, Lin JY, Wilensky DL, Igras VE, D’Orazio J, Fung CY, Schanbacher CF, Granter SR, Fisher DE. Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell. 2007; 128(5):853–64.
- Farhood H, Gao X, Son K. Cationic liposomes for direct gene-transfer in therapy of cancer and other diseases. Ann Ny Acad Sci. 1994; 716:23–35.
- Gallagher WM, Brown R. p53-oriented cancer therapies: current progress. Annals Oncol. 1999; 10:139–50.
- Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumour suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994; 54:4855–78.
- Hanahan D, Weinberg RA. The hallmarks of cancer. Cell.2000; 100:57–70.
- Howard MIC, Kershaw T, Gibb B. High efficiency gene transfer to the central nervous system of rodents and primates using herpes virus vectors lacking functional p27 and p34.5. Gene Ther. 1998; 5:1137–47.
- Idogawa M, Ohashi T, Sasaki Y, Maruyama R, Kashima L, Suzuki H, Tokino T. Identification and analysis of large intergenic non-coding RNAs regulated by p53 family members through a genome-wide analysis of p53-binding sites. Hum Mol Genet. 2014; 23:2847–57.
- Issaeva N, Friedler A, Bozko P, Wiman KG, Fersht AR, Selivanova G. Rescue of mutants of the tumour suppressor p53 in cancer cells by a designed peptide. Proc Nat Acad Sci. 2003; 100:13303–7.
- Jeffers JR, Parganas E, Lee Y, Yang C, Wang J. Puma is an essential mediator of p53-dependent and independent apoptotic pathways. Cancer Cell. 2003; 4(4):321–8.
- Joerger AC, Fersht AR. Structural biology of the tumor suppressor p53. Annu Rev Biochem. 2008; 77:557–82.
- Koshland DE. Molecule of the year. Science. 1993; 262(5142):1953.
- Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev. 2007; 87(1):99–163.
- Lesoonwood LA, Kim WH, Kleinman HK. Systemic gene-therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude-mice. Human Gene Ther. 1995; 6:395–405.
- Maier B, Gluba W, Bernier B. Modulation of mammalian life span by the short isoform of p53. Genes Dev. 2004; 18(3):306–19.
- Mohammad RM, Wu J, Azmi AS, Aboukameel A, Sosin A. An Mdm2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals. Mol. Cancer. 2009; 8:115.
- Moroni MC, Hickman ES, Denchi EL, Caprara G. Apaf-1 is a transcriptional target for E2F and p53. Nat Cell Biol. 2001; 3(6):552–8.
- Nemunaitis K, Nemunaitis S. Potential of Advexin: a p53 gene-replacement therapy in Li-Fraumeni syndrome. J Clin Oncol. 2008; 20:2408–18.
- Nielsen LL, Maneval DC. p53: Tumour suppressor gene therapy for cancer. Cancer Gene Ther. 1997; 4:129–38.
- Oconnor PM, Jackman J, Bae I. Characterization of the p53 tumour suppressor pathway in cell lines of the national cancer institute anticancer drug screen and correlations with the growth inhibitory potency of 123 anticancer agents. Cancer Res. 1997; 57:4285–300.
- Roth JA, Cristiano RJ. Gene therapy for cancer: What have we done and where are we going? J Nat Cancer Inst. 1997; 89:21–39.
- Sakaguchi K, Herrera JE, Saito S. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 1998; 12:2831–41.
- Shangary S, Wang S. Small-molecule inhibitors of the Mdm2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol. 2009; 49:223–41.
- Snyder EL, Meade BR, Saenz CC, Dowdy SF. Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. Proc Biol. 2004; 2:36.
- Takashi D, Bruce SE. Induction of wild-type p53 activity in human cancer cells by ribozyme that repair mutant p53 transcripts. Future Oncol. 2000; 4(6):759–68.
- Tamura M, Sasaki Y, Kobashi K, Takeda K, Nakagaki T, Idogawa M, Tokino T. CRKL oncogene is downregulated by p53 through miR-200s. Cancer Science. 2015; 106(7):1–8.
- Tamura M, Sasaki Y, Koyama R, Takeda K, Idogawa M, Tokino T. Forkhead transcription factor FOXF1 is a novel target gene of the p53 family and regulates cancer cell migration and invasiveness. Oncogene. 2014; 33:4837–46.
- Tang X, Zhu Y, Han L, Kim AL, Kopelovich L, Bickers DR, Athar M. CP-31398 restores mutant p53 tumour suppressor function and inhibits UVB-induced skin carcinogenesis in mice. J Clin Invest. 2002; 112(12):3753–64.
- Thomas M, Massimi P, Banks L. HPV-18 E6 inhibits DNA binding activity regardless of the oligomeric state of p53 or the exact p53 recognition sequence. Oncogene. 1996; 13:471–80.
- Vakhrusheva O, Smolka C, Gajawada P, Kostin S, Boettger T, Kubin T, Braun T. Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice. Circ Res. 2008; 102(6):703–10.
- Vegad JL. Neoplasia. In: A text book of veterinary general pathology (2nd edn). International book publishing distributing corporation, Lucknow. 2007; 277–335.
- Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000; 408:307–10.
- Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nature Reviews Cancer. 2013; 13:83–96.
- Wang W, El-Deiry WS. Restoration of p53 to limit tumour growth. Curr Opin Oncol. 2008; 20(1):90–6.
- Wolff JA, Malone RW, Williams P. Direct gene-transfer into mouse muscle in vivo. Science. 1990; 247:1465–8.
- Wu GS, Burns TF, McDonald ER. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet. 1997; 17(2):141–3.
- Wu N, Rollin J, Masse I, Lamartine J, Gidrol X. P53 regulates human keratinocytes proliferation by MYC –regulated gene network and differentiation commitment through cell adhesion-related gene network. The Journal of Biological Chemistry. 2012; 287(8):5627–38.
- Xu L, Pirollo KF, Chang EH. Transferrin-liposome-mediated p53 sensitisation of squamous cell carcinoma of the head and neck to radiation in vitro. Human Gene Ther. 1997; 8:467–75.
- Zhang J, Sun Q, Zhang Z, Ge S, Han ZG, Chen WT. Loss of microRNA-143/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop. Oncogene. 2013; 32:61–9.
- Safety Assessment of Cefquinome Following Multiple Intramuscular Administration Regarding Haematology of Cow Calves
Abstract Views :410 |
PDF Views:1
Authors
Neetu Rajput
1,
Neeru Yadav
1
Affiliations
1 Department of Pharmacology and Toxicology, College of Veterinary Science and Animal Husbandry, Mhow, Nanaji Deshmukh Veterinary Science University, Jabalpur (M.P.), IN
1 Department of Pharmacology and Toxicology, College of Veterinary Science and Animal Husbandry, Mhow, Nanaji Deshmukh Veterinary Science University, Jabalpur (M.P.), IN
Source
Toxicology International (Formerly Indian Journal of Toxicology), Vol 24, No 2 (2017), Pagination: 167-170Abstract
The present study was carried out to investigate haematological alterations induced after repeated intramuscular administration of cefquinome at the dose rate of 2 mg.kg-1 body weight in five healthy male cow calves. Blood samples were collected before administration of the drug which served as control (day 0). After administration of drugs, blood samples were collected at day 1st, 2nd, 3rd, 4th, 5th and 6th from jugular vein into Ethylene Diaminetetraacetic Acid Tripotassium Salt (K3EDTA) coated vacutainers for haematological parameters (Hemoglobin, Packed cell volume, total leukocyte count and differential leukocyte count) analysis. The results of the study clearly demonstrated that repeated intramuscular administration of cefquinome in therapeutic doses produced non-significant difference (p<0.05) in values of haematological parameters in cow calves when compared with control values (0 day). Lack of clinical signs of adverse reactions and absence of significant difference in haematological parameters following intramuscular administration, may open a new avenue for insight into the strategy for clinical treatment of various bacterial diseases in cow calves.Keywords
Cefquinome, Cow Calves, Safety Study, Cephalosporin, Antibiotic.References
- Barot P. Studies on pharmacokinetics of cefpirome in rats and effect of fever and co-administration of ketoprofen on pharmacokinetics of cefpirome along with its safety in goats.2011; Ph.D. Thesis.Anand Agricultural University. Gujarat, India.
- Guerin-Faublee V, Carret G and Houffschmitt P. In vitro activity of 10 antimicrobial agents against bacteria isolated from cows with clinical mastitis. Vet Rec. 2003; 152:466-471.
- Kadota T, Kondoh H, Chikazawa H, Kawano S, Kuroyanagi K, Ohta S, Ishikawa K, Takahashi N, Kohmura Hand Kai S. Four week repeated dose oral toxicity study of BMY-28142 cefepime in juvenile rats. Jpn J Antobiot. 1990; 43(7):1243-1259.
- Kadota T, Kondoh H, Chikazawa H, Kuroyanagi, K, Ishikawa K, Kawano S, Sakakura, K, Takahashi N,Funahashi N and Shimizu N. Cefepime (diHCl/L-arginine blend): intravenous continuous infusion and single dose subcutaneous toxicity study in rats and dogs. Jpn J Antibiot.1992; 45(6):612-9.
- Limbert M, Isert D, Klesel D, Markus A, Seeger K, Seibert G and Schrinner E. Antibacterial activity in-vitro and in-vivo and pharmacokinetics of cefquinome (HR 111V), a new broad spectrum cephalosporin.Antimicrobial Agents and Chemotherapy.1991; 35(1):14-19.
- Murphy SP, Erwin ME and Jones RN.Cefquinome (HR IIIV), in vitro evaluation of a broad spectrum cephalosporin indicated for infection in animals. DiagnMicrobiolInfect Dis. 1994; 20:49-55.
- Patel PN, Bhavsar SK, Patel UD, Pandey NK and Wadhwani KN. Safety evaluation of cefepimefollowing repeated intravenous administration in sheep.Indian Journal of Field Veterinarians. 2007; 2: 24-29.
- Rana MP. “Studies on effect of tolfenamic acid and bio-enhancertrikatu on pharmacokinetics of cefquinome and safety of simultaneous administration of cefquinome and tolfenamic acid in patanwadi sheep”.2014; M.V.Sc. Thesis. Anand Agricultural University. Gujarat, India.
- Schalm OW. Veterinary Haematology.(2ndedn.),1967; Lea and Febiger, Philadelphia, USA.
- Shpigel NY,Levin D, Winkler M, Saran A, Ziv G and Bottner A. Efficacy of cefquinome for treatment of cows with mastitis experimentally induced using Escherichia coli. J Dairy Sci. 1997; 80:318-323.
- Tiwari S. Studies on effect of febrile condition and coadministration of meloxicamonpharmacokinetics of cefquinome and its safety in goats. 2014; Ph.D. thesis (Pharmacology and toxicology), Navsari Agriculture University, Navsari.
- Uney K, Altan F and Elmas M. Development and validation of a high performance liquid chromatography method for determination of cefquinome concentrations in sheep plasma and its application to pharmacokinetic studies.AntimicrobAgentsChemother. 2011; 55(2):854-859.
- Biochemical Alterations Following Repeated Intramuscular Administration of Cefquinome in Cow Calves during its Safety Assessment
Abstract Views :396 |
PDF Views:1
Authors
Neetu Rajput
1,
Neeru Yadav
1
Affiliations
1 Department of Pharmacology and Toxicology, College of Veterinary Science and Animal Husbandry, Mhow, IN
1 Department of Pharmacology and Toxicology, College of Veterinary Science and Animal Husbandry, Mhow, IN
Source
Toxicology International (Formerly Indian Journal of Toxicology), Vol 24, No 3 (2017), Pagination: 240-243Abstract
The present study was carried out to investigate biochemical alterations induced after repeated intramuscular administration of cefquinome at the dose rate of 2 mg.kg-1 body weight in five healthy cow calves during its safety assessment study. Blood samples were collected before administration of the drug which served as control (day 0). After administration of drugs, blood samples were collected at day 1st, 2nd, 3rd, 4th, 5th and 6th from jugular vein into vacutainers without K3EDTA for serum biochemical parameters (serum aspartate aminotransferase (AST), serum alanine aminotransferase (ALT), serum lactate dehydrogenase (LDH), serum alkaline phosphatase (AKP), serum acid phosphatase (ACP) and serum bilirubin) analysis. The results of the study clearly demonstrated that repeated intramuscular administration of cefquinome in therapeutic dose produced non-significant (p<0.05) difference in values of serum biochemical parameters in cow calves when compared with control values (0 day). Lack of clinical signs of adverse reactions and absence of significant difference in serum biochemical parameters following intramuscular administration of cefquinome, may open a new avenue for insight into the strategy for clinical treatment of various bacterial diseases in cow calves.Keywords
Cefquinome, Cow Calves, Safety Study, Cephalosporin, Antibiotic.References
- Aarestrup F.M and Skov RL. Evaluation of ceftiofur and cefquinome for phenotypic detection of methicillin resistance in Staphylococcus aureus using disk diffusion testing and MIC determinations. Journal of Veterinary Microbiology. 2010; 140(1-2): 176-179.
- Barot P. Studies on pharmacokinetics of cefpirome in rats and effect of fever and co-administration of ketoprofen on pharmacokinetics of cefpirome along with its safety in goats.2011; Ph.D. Thesis. Anand Agricultural University. Gujarat, India.
- Bryskier A. New concepts in the field of cephalosporins: C-3 quaternary ammonium cephems (Group 1V). Clinical Microbiology and Infections. 1997; 3(1): 1-6.
- Donowitz GR. Third generation cephalosporin. Infect. Dis. Clin. North. Am. 1989; 3 (3): 595-612.
- Kadota T, Kondoh H, Chikazawa H, Kawano S, Kuroyanagi K, Ohta S, Ishikawa K, Takahashi N, Kohmura H and Kai S. Four week repeated dose oral toxicity study of BMY-28142 cefepime in juvenile rats. Jpn J Antobiot. 1990; 43(7): 1243-1259.
- Kadota T, Kondoh H, Chikazawa H, Kuroyanagi K, Ishikawa K, Kawano S, Sakakura K, Takahashi N, Funahashi N and Shimizu N. Cefepime (diHCl/L-arginine blend): intravenous continuous infusion and/orsingle dose subcutaneous toxicity study in rats and dogs. Jpn J Antibiot. 1992; 45(6):612-9.
- Kai S, Kohmura H, Ishikawa K, Kawano S, Sakai A, Kuroyanagi K, Kadota T and Takahashi N. Reproductive and developmental toxicity studies on cefepimedihydrochlorideadministered subcutaneously to rats during the premating, gestation and lactation periods. Jpn J Antibiot. 1992; 45(6):642-60.
- Kalman D and Barriere SL. Review of the pharmacology, pharmacokinetics, and clinical use of cephalosporins.Texas heart institute J. 1990; 13(3): 203-215.
- Limbert M, Isert D, Klesel D, Markus A, Seeger K, Seibert G and Schrinner E. Antibacterial activity in-vitro and in-vivo and pharmacokinetics of cefquinome (HR 111V), a new broad spectrum cephalosporin.Antimicrobial Agents and Chemotherapy. 1991; 35(1):14-19.
- Maden M, Tras B, Bas AL, Elmas M, Yazar E and Birdane FM. Investigation of biochemical and haematological side-effects of cefquinome in healthy dogs. Veterinary Quarterly. 2001; 23(1): 32-34.
- Patel HB, Patel NN, Patel SD, Dewda S, Patel JH, Bhavsar SK andThaker AM. Effect of Ketoprofen Co-administration and FebrileState on Pharmacokinetic of Cefepime in Goats. Asian Journal of Animal andVeterinary Advances. 2012; 7: 46-53.
- Patel PN, Bhavsar SK, Patel UD, Pandey NK and Wadhwani KN. Safety evaluation of cefepime following repeated intravenous administration in sheep. Indian Journal of Field Veterinarians.2007; 2: 24-29.
- Rana M.P. “Studies on effect of tolfenamic acid and bioenhancertrikatu on pharmacokinetics of cefquinome and safety of simultaneous administration of cefquinome and tolfenamic acid in patanwadi sheep”. 2014; M.V.Sc. Thesis. Anand Agricultural University. Gujarat, India.
- Rankin GO and Sutherland CH. Nephrotoxicity of aminoglycosides and cephalosporins in combination. Adverse Drug React Acute Poisioning Rev.1989; 8(2): 73-88.
- Teitz NW. Textbook of clinical chemistry. 1999; Publ. W.B. Saunders Co. Philadelphia, pp. 582-584.
- Tiwari S. Studies on effect of febrile condition and coadministration of meloxicam on pharmacokinetics of cefquinome and its safety in goats.2014; Ph.D. thesis (Pharmacology and toxicology), Navsari Agriculture University, Navsari.